Kazia Therapeutics (NASDAQ:KZIA) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Kazia Therapeutics (NASDAQ:KZIA) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $2.00 price target on the stock.

Kazia Therapeutics Stock Down 37.7 %

KZIA stock opened at $0.56 on Friday. Kazia Therapeutics has a 12 month low of $0.19 and a 12 month high of $1.58. The firm’s 50-day moving average is $0.30 and its 200 day moving average is $0.31.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kazia Therapeutics stock. Platinum Investment Management Ltd. purchased a new position in Kazia Therapeutics Limited (NASDAQ:KZIA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,821,887 shares of the company’s stock, valued at approximately $801,000. Platinum Investment Management Ltd. owned 11.15% of Kazia Therapeutics at the end of the most recent reporting period. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.